Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
Breaking: Ultra-High-Cost Gene Therapies Set to Influence Major Pharmacy Shifts
AJMC December 9, 2024
Leaders of the American Society of Health-System Pharmacists (ASHP) say the time is now to prepare for providing innovative gene and cell therapies.
The advent of “ultra-high-cost” treatments like gene and cell therapies will create exciting new therapies for patients, but will also likely create economic, equity, and workforce issues for health system pharmacies, a new report warns. The 2025 American Society of Health-System Pharmacists (ASHP)/ASHP Pharmacy Forecast and its foundation urges health systems to carefully prepare for the emerging new era.1
To date, the FDA has approved 21 gene and cell therapies for cancer, blood disorders, and retinal disease, among others. That number is expected to climb significantly in future years. While such therapies can lead to dramatic improvements...
Today's Sponsors
Today's Sponsor